Oncotelic Therapeutics Stock Performance
| OTLC Stock | USD 0.04 0.01 10.00% |
The company holds a Beta of 0.0258, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oncotelic Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncotelic Therapeutics is expected to be smaller as well. At this point, Oncotelic Therapeutics has a negative expected return of -0.82%. Please make sure to check Oncotelic Therapeutics' jensen alpha and the relationship between the potential upside and price action indicator , to decide if Oncotelic Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Oncotelic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Oncotelic |
Oncotelic Therapeutics Relative Risk vs. Return Landscape
If you would invest 9.00 in Oncotelic Therapeutics on November 16, 2025 and sell it today you would lose (4.50) from holding Oncotelic Therapeutics or give up 50.0% of portfolio value over 90 days. Oncotelic Therapeutics is currently does not generate positive expected returns and assumes 7.8425% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of otc stocks are less volatile than Oncotelic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncotelic Therapeutics Target Price Odds to finish over Current Price
The tendency of Oncotelic OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.04 | 90 days | 0.04 | close to 99 |
Based on a normal probability distribution, the odds of Oncotelic Therapeutics to move above the current price in 90 days from now is close to 99 (This Oncotelic Therapeutics probability density function shows the probability of Oncotelic OTC Stock to fall within a particular range of prices over 90 days) .
Oncotelic Therapeutics Price Density |
| Price |
Predictive Modules for Oncotelic Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Oncotelic Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Oncotelic Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Oncotelic Therapeutics is not an exception. The market had few large corrections towards the Oncotelic Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Oncotelic Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oncotelic Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.93 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.13 |
Oncotelic Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncotelic Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncotelic Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oncotelic Therapeutics generated a negative expected return over the last 90 days | |
| Oncotelic Therapeutics has high historical volatility and very poor performance | |
| Oncotelic Therapeutics has some characteristics of a very speculative penny stock | |
| Oncotelic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Oncotelic Therapeutics currently holds 9.8 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Oncotelic Therapeutics has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncotelic Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Oncotelic Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncotelic Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncotelic to invest in growth at high rates of return. When we think about Oncotelic Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.39 M) with profit before overhead, payroll, taxes, and interest of 1.74 M. | |
| Oncotelic Therapeutics currently holds about 399.77 K in cash with (4.43 M) of positive cash flow from operations. | |
| Roughly 56.0% of Oncotelic Therapeutics outstanding shares are owned by corporate insiders | |
| Latest headline from massdevice.com: Medtronic stock gets a ratings boost on new products |
Oncotelic Therapeutics Fundamentals Growth
Oncotelic OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Oncotelic Therapeutics, and Oncotelic Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncotelic OTC Stock performance.
| Return On Equity | 0.5 | |||
| Return On Asset | -0.13 | |||
| Current Valuation | 31.34 M | |||
| Shares Outstanding | 391.11 M | |||
| Price To Earning | 2.16 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 8.40 X | |||
| EBITDA | (8.45 M) | |||
| Cash And Equivalents | 399.77 K | |||
| Total Debt | 9.8 M | |||
| Debt To Equity | 0.40 % | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (4.43 M) | |||
| Earnings Per Share | 0.02 X | |||
| Total Asset | 23.61 M | |||
About Oncotelic Therapeutics Performance
By analyzing Oncotelic Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Oncotelic Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncotelic Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncotelic Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes and CA4P for the treatment of advanced metastatic melanoma. Oncotelic Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.Things to note about Oncotelic Therapeutics performance evaluation
Checking the ongoing alerts about Oncotelic Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Oncotelic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncotelic Therapeutics generated a negative expected return over the last 90 days | |
| Oncotelic Therapeutics has high historical volatility and very poor performance | |
| Oncotelic Therapeutics has some characteristics of a very speculative penny stock | |
| Oncotelic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Oncotelic Therapeutics currently holds 9.8 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Oncotelic Therapeutics has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncotelic Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Oncotelic Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncotelic Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncotelic to invest in growth at high rates of return. When we think about Oncotelic Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.39 M) with profit before overhead, payroll, taxes, and interest of 1.74 M. | |
| Oncotelic Therapeutics currently holds about 399.77 K in cash with (4.43 M) of positive cash flow from operations. | |
| Roughly 56.0% of Oncotelic Therapeutics outstanding shares are owned by corporate insiders | |
| Latest headline from massdevice.com: Medtronic stock gets a ratings boost on new products |
- Analyzing Oncotelic Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncotelic Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Oncotelic Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncotelic Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncotelic Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Oncotelic Therapeutics' otc stock. These opinions can provide insight into Oncotelic Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oncotelic OTC Stock analysis
When running Oncotelic Therapeutics' price analysis, check to measure Oncotelic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncotelic Therapeutics is operating at the current time. Most of Oncotelic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncotelic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncotelic Therapeutics' price. Additionally, you may evaluate how the addition of Oncotelic Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |